Currently available data cannot establish the safety and efficacy of osteoporosis medications for patients with chronic kidney disease (CKD), concludes a meta-analysis in Annals of Internal Medicine.
A systematic review identified 13 randomized trials, including a total of 9850 patients, evaluating the clinical benefits and safety outcomes of osteoporosis medications in CKD patients. The medications studied were bisphosphonates, teriparatide, raloxifene, and denosumab. Outcomes of interest were bone mineral density (BMD), fractures, mortality, and adverse events. Kidney transplant recipients were enrolled in six trials, postmenopausal women with CKD in four, and patients with CKD stage 3 to 5 or on